TheBodyPro: Expert analysis from Benjamin Young, M.D., Ph.D.
It’s been a year since FDA gave the green light to lenacapavir for PrEP, our first six-monthly injection for HIV prevention. Late-stage clinical trials touted near-perfect efficacy — but how have things actually worked out in the clinic?
New results from a US study on implementation outcomes remind us that trial data only gets us so far — and also gives us some important context to take into the next conversation we have with a patient about starting PrEP.
This analysis reports the results of a retrospective multi-center cohort study of lenacapavir (LEN) PrEP from 17 academic and community-based HIV prevention programs in the United States. The study evaluated individuals who received at least one LEN injection between June and December 2025 and abstracted data from standardized electronic health records.
Read the full analysis here.
Source : TheBodyPro
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.